Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S318000, C536S026800
Reexamination Certificate
active
07105527
ABSTRACT:
The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acyl-2′,3′-dideoxy-5-fluorocytidine or N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4957924 (1990-09-01), Beauchamp
patent: 5561120 (1996-10-01), Lin et al.
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 5905070 (1999-05-01), Schinazi et al.
patent: 6232300 (2001-05-01), Schinazi et al.
patent: 2003/0087873 (2003-05-01), Stuyver et al.
patent: 99493 (1984-02-01), None
patent: 311100 (1989-04-01), None
patent: 409 227 (1989-05-01), None
patent: 8901258 (1991-01-01), None
patent: WO 99/43691 (1999-02-01), None
patent: WO 9926958 (1999-06-01), None
Zhang et al. J. Org. Chem. 65, 7075-7082, 2000.
Mikhailopulo et al. J. Med. Chem. 34, 2195-2202, 1991.
Czochralska et al. Romanian Journal of Biophysics 5(4): 199-208, 1995.
Giri et al. Nucleosides & Nucleotides 15(1-3): 183-204, 1996.
Luzzio et al. J. Org. Chem. 59, 7267-7272, 1994.
Aerschot et al. J. Med. Chem. 33, 1833-1839, 1990.
Lee et al. J. Med. Chem. 42, 1320-1328, 1999.
Bacheler LT, Paul M, Otto MJ, Jadhav PK, Stone BA & Miller JA (1994) An assay for HIV RNIn infected cell lysates, and its use for rapid evaluation of antiviral efficacy. Antivir. Chem. Chemother. 5:111-121.
Charvet A-S, Camplo M, Faury P, Graciet JC, Mourier N, Chermann JC & Kraus JL (1994) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates. J. Med. Chem. 37:2216-2223.
Chou T.-C. & Talalay P.Adv. Enzyme Regul.1984, 22, 27-55.
Gulbis et al. (1993) Structure of a dideoxynucleoside active against the HIV (AIDS) virus. Acta Cryst. C49, 1095-1097), N4-acetyl-2'-3'-didehydro-2',3'-dideoxy-5-flurocytidine, and N4-isopropyl-2',3'-didehydro-2',3'-dideoxy-5-flurocytidine.
Hosteller, K.Y., D.D. Richman, D.A. Carson, L.M. Stuhmiller, G.M. T. van Wijk, and H. van den Bosch, “Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3,-deoxythymidine,”Antimicrob. Agents Chemother., 1992, 36, 2025-2029.
Hostetlet, K.Y., L.M. Stuhmiller, H.B. Lenting, H. van den Bosch, and D.D. Richman, “Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides.”J. Biol. Chem., 1990, 265, 61127.
Jadhav PK & MacKay MF (1997) Cyclic urea amide: HIV-1 protease inhibitors with low nanomolar potency against both wild types and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40:181-190).
Kawaguchi et al., Studies on 2',3'-dideoxy-2', 3'-didehydropyrimidine nucleosides. II. N4-benzoyl-2',3'-dideoxy-2',3'-didehydrochytidine as a prodrug of 2',3'-dideoxy-2',3'-didehydrocytidine (DDCN), Chem. Pharm. Bull. (1989), 37(9), 2547-9), N4-benzoyl-2',3'-dideoxycytidine.
Kucera, L.S., N. Iyer, E. Leake, A. Raben, Modest E.K., D.L.W., and C. Piantadosi, “Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation,”AIDS Res. Hum. Retroviruses, 1990, 6, 491-501.
Ladner S.K., Otto M.J., Barker C.S., Zaifret K., Wang G.H., Guo J.T., Seeger C. & King R.W.Antimicrob. Agents Chemother.1997, 41, 1715-1720).
Mauldin et al. (1998) Synthesis and antiviral activity of prodrugs of the nucleoside 1-[2',3'-dideoxy-3'-C-(hydroxymethyl)-β-D-erythropentofuranosyl] cytosine. Bioorg. Med. Chem. 6, 577-585).
Piantadosi, C. J. Marasco C.J., S.L. Morris-Natschke, K.L. Meyer, F. Gumus, J.R. Surles, K.S. Ishaq, L.S: Kucera, N. Iyer, C.A. Wallen, S. Piantadosi, and E.J. Modest, “Synthesis and evaluation of novel ether lipid nucleosides conjugates for anti-HIV activity,”J. Med. Chem., 1991, 34, 1408-1414.
Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M. Jr., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P.A., Painter G., Choi W.-B., Liotta D.C. Antimicrob. Agents Chemother. 1992, 36, 2423.
Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D.L., Xie M.-Y., Hart G.C., Smith G.A. & Hahn E.F.Antimicrob Agents Chemother.1990, 34, 1061-1067).
Shi et al. (1999) Synthesis and biological evaluation of 2',3'-didehydro-2',3'-dideoxy-5-flurocytidine (d4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. J. Med. Chem. 42, 859-867).
Otto Michael J.
Shi Junxing
Watanabe Kyoichi A.
Balasubramanian Venkataraman
Merchant & Gould P,C,
LandOfFree
N 4 -acylcytosine nucleosides for treatment of viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N 4 -acylcytosine nucleosides for treatment of viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N 4 -acylcytosine nucleosides for treatment of viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553666